Takeda Pharmaceutical Company Ltd
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 307
- Registration Number
- NCT02427958
Phase 1 Single Subcutaneous Dose Study of MLN1202
Phase 1
Withdrawn
- Conditions
- Healthy Japanese and Caucasian Male Adults
- Interventions
- Drug: MLN1202Drug: MLN1202 Placebo
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Takeda
- Registration Number
- NCT02426021
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 101
- Registration Number
- NCT02425111
Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore
Phase 2
Completed
- Conditions
- Dengue Fever
- Interventions
- Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)Biological: Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 351
- Registration Number
- NCT02425098
- Locations
- πΈπ¬
Changi General Hospital, Singapore, Singapore
πΈπ¬Tan Tock Seng Hospital, Singapore, Singapore
πΈπ¬Singapore General Hospital, Singapore, Singapore
Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveillance)
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 147
- Registration Number
- NCT02415712
- Locations
- π―π΅
Takeda Sponsored Site, Tokyo, Japan
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 120
- Registration Number
- NCT02413255
Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria
Phase 2
Withdrawn
- Conditions
- Diabetic Nephropathy
- Interventions
- Drug: MLN1202 PlaceboDrug: MLN1202
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Takeda
- Registration Number
- NCT02410499
A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.
Phase 4
Withdrawn
- Conditions
- Essential Hypertension With Stable Angina and Dyslipidemia
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Takeda
- Registration Number
- NCT02400775
A Bioequivalence Study of TAK-536 Pediatric Formulation
Phase 1
Completed
- Conditions
- Japanese Healthy Adult Males
- Interventions
- Drug: TAK-536 TabletDrug: TAK-536 Dry Syrup FormulationDrug: TAK-536 Ganule Formulation
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 52
- Registration Number
- NCT02401464
Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TAK-385 T2 FormulationDrug: TAK-385 T4 Formulation BDrug: TAK-385 T4 Formulation C
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 54
- Registration Number
- NCT02396147
Β© Copyright 2025. All Rights Reserved by MedPath